Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Deferred Taxes (2016 - 2020)

Historic Deferred Taxes for Enanta Pharmaceuticals (ENTA) over the last 7 years, with Q3 2020 value amounting to $15.0 million.

  • Enanta Pharmaceuticals' Deferred Taxes rose 136362.87% to $15.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $10.6 million, marking a year-over-year increase of 43804.97%. This contributed to the annual value of $345000.0 for FY2021, which is 9674.77% down from last year.
  • Enanta Pharmaceuticals' Deferred Taxes amounted to $15.0 million in Q3 2020, which was up 136362.87% from -$3.1 million recorded in Q2 2020.
  • In the past 5 years, Enanta Pharmaceuticals' Deferred Taxes registered a high of $15.0 million during Q3 2020, and its lowest value of -$3.8 million during Q2 2017.
  • Moreover, its 5-year median value for Deferred Taxes was -$918000.0 (2018), whereas its average is $263052.6.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Deferred Taxes plummeted by 581666.67% in 2016 and then surged by 136362.87% in 2020.
  • Enanta Pharmaceuticals' Deferred Taxes (Quarter) stood at -$1.9 million in 2016, then surged by 239.37% to $2.7 million in 2017, then plummeted by 134.49% to -$918000.0 in 2018, then soared by 171.57% to $657000.0 in 2019, then skyrocketed by 2179.15% to $15.0 million in 2020.
  • Its Deferred Taxes stands at $15.0 million for Q3 2020, versus -$3.1 million for Q2 2020 and -$1.9 million for Q1 2020.